Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Jefferies Group lowered their FY2017 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research report issued on Monday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings of ($0.53) per share for the year, down from their previous forecast of ($0.52). Jefferies Group has a “Buy” rating and a $21.00 price objective on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ Q4 2017 earnings at ($0.19) EPS, FY2018 earnings at ($0.34) EPS, FY2019 earnings at $1.37 EPS, FY2020 earnings at $1.30 EPS and FY2021 earnings at $1.71 EPS.

VNDA has been the topic of a number of other research reports. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Piper Jaffray Companies restated an “overweight” rating and issued a $23.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, June 27th. HC Wainwright set a $18.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and an average target price of $21.29.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/11/analysts-set-expectations-for-vanda-pharmaceuticals-inc-s-fy2017-earnings-vnda.html.

Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 16.80 on Wednesday. Vanda Pharmaceuticals has a 12 month low of $12.70 and a 12 month high of $18.99. The firm’s 50-day moving average is $17.45 and its 200-day moving average is $15.62. The firm’s market capitalization is $753.61 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.18. The firm had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. Vanda Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.01 earnings per share.

A number of institutional investors have recently made changes to their positions in VNDA. Legal & General Group Plc boosted its position in Vanda Pharmaceuticals by 37.4% during the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares during the period. Virginia Retirement Systems ET AL bought a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $193,000. Dynamic Technology Lab Private Ltd bought a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $196,000. Kopp Investment Advisors LLC bought a new stake in Vanda Pharmaceuticals during the second quarter worth approximately $196,000. Finally, American International Group Inc. boosted its position in Vanda Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 1,491 shares during the period. 86.49% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.